{"id":"novolin-70-30","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":{"setId":"e825d7e9-467c-4f50-a6d6-f2602449c1de","title":"NOVOLIN 70/30 (HUMAN INSULIN) INJECTION, SUSPENSION [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Novolin 70/30 contains 70% NPH insulin (intermediate-acting) and 30% regular insulin (short-acting). The regular insulin component acts quickly to lower postprandial glucose, while the NPH component provides sustained glucose control throughout the day and overnight. Together, they mimic the body's natural biphasic insulin secretion pattern.","oneSentence":"Novolin 70/30 is a fixed-ratio insulin combination that replaces or supplements the body's natural insulin to regulate blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:20:36.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07485101","phase":"NA","title":"Glycemic Targets During CPB in Elderly Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-04-01","conditions":"Glycemic Management During CPB in Elderly Diabetic Cardiac Surgery","enrollment":3000},{"nctId":"NCT03624062","phase":"PHASE1","title":"MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-08-31","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT07403604","phase":"PHASE1","title":"Effect of Insulin Lowering on Lipogenesis","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-04","conditions":"Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease","enrollment":25},{"nctId":"NCT06090864","phase":"PHASE1, PHASE2","title":"ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-04-25","conditions":"Hodgkin Lymphoma, Relapse, Refractory","enrollment":31},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT05614089","phase":"PHASE4","title":"Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings","status":"COMPLETED","sponsor":"Jing Luo","startDate":"2023-03-15","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes","enrollment":400},{"nctId":"NCT06968286","phase":"NA","title":"The Effect of Locally Dilvered Ciprofloxacine Loaded Injectable Platelet-rich Fibrin as an Adjunct to Non-surgical Periodontal Therapy on the Gingival Crevicular Level of Interleukin 6","status":"COMPLETED","sponsor":"Suez Canal University","startDate":"2025-01-01","conditions":"Periodontitis Stage II","enrollment":60},{"nctId":"NCT04088981","phase":"NA","title":"Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Physicians Committee for Responsible Medicine","startDate":"2025-07","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT06876207","phase":"","title":"Real-world Study on the Effectiveness and Safety of Control-IQ Technology in Teenagers With Type 1 Diabetes Engaging in Regular Physical Activity","status":"RECRUITING","sponsor":"Bruno Bombaci","startDate":"2025-06-01","conditions":"Type 1 Diabetes Mellitus","enrollment":50},{"nctId":"NCT06668714","phase":"NA","title":"Does Co-administration of Lactate Affect Postprandial Nutrient Absorption and Fat Disposition?","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-08-22","conditions":"Pre Diabetes, Metabolic Syndrome","enrollment":25},{"nctId":"NCT06925334","phase":"PHASE4","title":"A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-05-20","conditions":"Type 2 Diabetic Patients","enrollment":170},{"nctId":"NCT06911879","phase":"NA","title":"The Effect of Ketogenic-caloric Restricted Diet on Metabolic Endotoxemia in Prediabetic Obese Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Jordan","startDate":"2025-04-05","conditions":"Insulin Resistance, Metabolic Endotoxemia, Inflammation Biomarkers","enrollment":90},{"nctId":"NCT06856720","phase":"NA","title":"Impact of NMES, Aerobic, and Resistance Exercise on Glycemic Control in Older Adults With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Carlos Tavares","startDate":"2025-05-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":105},{"nctId":"NCT06656377","phase":"NA","title":"Optimization of Exercise Protocol for Prediabetic Population in Postprandial State","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2022-09-15","conditions":"Prediabetes, Exercise, Blood Glucose Profile","enrollment":25},{"nctId":"NCT06601660","phase":"NA","title":"Metabolic Investigation, Physical Performance, Physical Training At Different Times of the Day in Obese Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of Minas Gerais","startDate":"2024-09-16","conditions":"Obesity Type I and II, Obesity and Overweight","enrollment":60},{"nctId":"NCT05017675","phase":"NA","title":"Effect of Dietary SFA and Fructose on Hepatic Insulin Sensitivity","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2021-11-08","conditions":"Insulin Resistance","enrollment":20},{"nctId":"NCT04791787","phase":"NA","title":"Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2020-11-25","conditions":"Glucose Metabolism Disorders (Including Diabetes Mellitus), Energy Supply; Deficiency, Type 2 Diabetes","enrollment":35},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT00671008","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-12","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT00101751","phase":"PHASE4","title":"INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":4877},{"nctId":"NCT01486862","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00476437","phase":"PHASE3","title":"Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":81},{"nctId":"NCT01308437","phase":"PHASE3","title":"Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics","status":"TERMINATED","sponsor":"Wockhardt","startDate":"2011-03","conditions":"Type I Diabetes","enrollment":134},{"nctId":"NCT00858273","phase":"NA","title":"Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2008-03","conditions":"Diabetes Mellitus, Type 1","enrollment":41},{"nctId":"NCT05095259","phase":"NA","title":"Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes","status":"UNKNOWN","sponsor":"Nordsjaellands Hospital","startDate":"2019-12-16","conditions":"Type1diabetes","enrollment":60},{"nctId":"NCT05558488","phase":"NA","title":"The Effect of a Meatless,Keto Restrictive Diet on Body Composition,Strength Capacity,Oxidative Stress,Immune Response","status":"COMPLETED","sponsor":"Katarzyna Siedzik","startDate":"2019-10-01","conditions":"Body Weight, Oxidative Stress, Trimethylamine N-oxide","enrollment":14},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT03916601","phase":"PHASE1","title":"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-12-13","conditions":"Type 1 Diabetes","enrollment":52},{"nctId":"NCT03384719","phase":"NA","title":"The Effect of Milk Protein vs Blends of Milk and Plant Protein on Growth Markers in 7-8 Year Old Healthy Danish Children","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2018-01-18","conditions":"Growth Acceleration, Growth; Stunting, Nutritional","enrollment":129},{"nctId":"NCT01293396","phase":"PHASE4","title":"Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT01484457","phase":"EARLY_PHASE1","title":"Controlled Insulin Delivery: Combining Technology With Treatment","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2008-07","conditions":"Diabetes Mellitus, Type 1","enrollment":19},{"nctId":"NCT04726657","phase":"NA","title":"Comparison of Two Biphasic Insulin Regimens","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2016-01-18","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT04392882","phase":"NA","title":"Effects of Legumes Consumption on Weight Reduction","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-03-01","conditions":"Obese","enrollment":400},{"nctId":"NCT04635202","phase":"NA","title":"Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-09-09","conditions":"Metabolic Syndrome","enrollment":60},{"nctId":"NCT03994276","phase":"NA","title":"The Postprandial Effects of Chick-Pea Consumption on Glucose, Insulin, and Gut Hormone Responses (PEA-POD).","status":"COMPLETED","sponsor":"King's College London","startDate":"2019-06-25","conditions":"Postprandial Period","enrollment":29},{"nctId":"NCT04498884","phase":"NA","title":"Comparative Study of the Pharmacokinetics of Rinsulin® Mix 30/70, Suspension for Subcutaneous Administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) and Humulin® M3, Suspension for Subcutaneous Administration, 100 IU / ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-07-18","conditions":"Bioequivalence","enrollment":32},{"nctId":"NCT03862690","phase":"","title":"A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2020-05-28","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT04226105","phase":"PHASE3","title":"Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Geropharm","startDate":"2020-01-20","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":264},{"nctId":"NCT02678390","phase":"NA","title":"Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2015-09","conditions":"Prediabetic State","enrollment":20},{"nctId":"NCT00821795","phase":"PHASE4","title":"Veterans Inpatient Insulin Study and Transition to Outpatient Therapy","status":"COMPLETED","sponsor":"Dennis G. Karounos, M.D.","startDate":"2009-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT02660242","phase":"PHASE2","title":"The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 1","enrollment":16},{"nctId":"NCT04022291","phase":"PHASE1","title":"Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30","status":"COMPLETED","sponsor":"Biocon Limited","startDate":"2019-06-15","conditions":"Healthy Volunteer","enrollment":78},{"nctId":"NCT04184492","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-04-15","conditions":"Clamp Study","enrollment":34},{"nctId":"NCT01474018","phase":"PHASE4","title":"QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT02987751","phase":"PHASE4","title":"A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2016-12-29","conditions":"Type2 Diabetes","enrollment":200},{"nctId":"NCT03087721","phase":"NA","title":"High-intensity Interval, Low Volume Training in Metabolic Syndrome","status":"COMPLETED","sponsor":"Universidad de Antioquia","startDate":"2017-03-01","conditions":"Metabolic Syndrome, Insulin Resistance","enrollment":60},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT02582242","phase":"PHASE4","title":"Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-19","conditions":"Diabetes, Type 2 Diabetes Mellitus","enrollment":437},{"nctId":"NCT02762578","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":543},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT01855243","phase":"NA","title":"Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM","status":"COMPLETED","sponsor":"Cairo University","startDate":"2010-03","conditions":"Diabetes Mellitus (DM)","enrollment":63},{"nctId":"NCT01059812","phase":"PHASE3","title":"A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-02-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":424},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT02449603","phase":"PHASE4","title":"Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":150},{"nctId":"NCT03612778","phase":"NA","title":"Modification of Diet in Renal Transplantation (MDRT)","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2018-11-15","conditions":"Kidney Transplant; Complications","enrollment":86},{"nctId":"NCT02648217","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-01-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":263},{"nctId":"NCT03374774","phase":"","title":"A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":516},{"nctId":"NCT00659282","phase":"","title":"Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-09-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":57610},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT03333525","phase":"NA","title":"Does Protein and Fat Content of Meal Increase Glucose Concentrations","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2013-09-10","conditions":"Type 1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01538511","phase":"PHASE1","title":"Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT02568384","phase":"NA","title":"Evaluation of an Ascensia Blood Glucose Meter and App System","status":"COMPLETED","sponsor":"Ascensia Diabetes Care","startDate":"2015-10","conditions":"Diabetes Mellitus","enrollment":45},{"nctId":"NCT00766298","phase":"NA","title":"Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2004-06","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT01589653","phase":"PHASE4","title":"Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":155},{"nctId":"NCT03106870","phase":"NA","title":"Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2016-06","conditions":"Gestational Diabetes Mellitus in Pregnancy","enrollment":62},{"nctId":"NCT00613951","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":182},{"nctId":"NCT01971047","phase":"PHASE4","title":"Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2013-10","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":""},{"nctId":"NCT00184600","phase":"PHASE3","title":"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00564668","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-06-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":126},{"nctId":"NCT01467401","phase":"PHASE4","title":"Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":292},{"nctId":"NCT01523041","phase":"PHASE1","title":"Comparison of Two Formulations of Biphasic Insulin Aspart 70","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-11-03","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01704378","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04-18","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00184626","phase":"PHASE4","title":"Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":97},{"nctId":"NCT01527539","phase":"PHASE3","title":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-11-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT00617565","phase":"PHASE3","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-07-08","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":219},{"nctId":"NCT01519674","phase":"PHASE4","title":"Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT01527565","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-01-20","conditions":"Diabetes, Healthy","enrollment":30},{"nctId":"NCT01536626","phase":"","title":"Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":211},{"nctId":"NCT00592969","phase":"PHASE4","title":"Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":164},{"nctId":"NCT01427920","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":348},{"nctId":"NCT01697631","phase":"PHASE4","title":"Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-07-22","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":131},{"nctId":"NCT00791895","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-06-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":102},{"nctId":"NCT01618214","phase":"PHASE4","title":"Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT01123980","phase":"PHASE4","title":"Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT01486381","phase":"PHASE3","title":"Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-03-20","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT01467375","phase":"PHASE3","title":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-01-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00469092","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01174303","phase":"PHASE1","title":"A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT01051102","phase":"PHASE1","title":"Effect of NN5401 in Japanese Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":21},{"nctId":"NCT00993096","phase":"PHASE1","title":"Investigation of the Response Relationship of NN5401 in Type 1 Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT00842361","phase":"PHASE2","title":"Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT01542424","phase":"","title":"An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-03","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1889},{"nctId":"NCT00869908","phase":"","title":"Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66726},{"nctId":"NCT01068652","phase":"PHASE4","title":"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":403},{"nctId":"NCT03018665","phase":"PHASE4","title":"A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2017-02","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT00097877","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":293},{"nctId":"NCT00775736","phase":"","title":"Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":611},{"nctId":"NCT00605111","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":193},{"nctId":"NCT00097279","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"19991018","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20180601","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19960613","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20020311","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20221123","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19980724","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20160108","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19950522","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20010221","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19970620","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20180601","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19940103","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20090615","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19970102","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19940623","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20101227","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19940426","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19940531","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19930326","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20020619","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19930326","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19920313","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20011219","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20000615","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20020411","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20000316","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19970410","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20001213","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19990512","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19970128","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20011210","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19970804","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19940104","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20090717","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20191115","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19970416","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20130309","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19940623","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20100625","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19940523","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19940616","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19940107","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20100625","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20020110","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19911007","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20020415","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"19910625","type":"ORIG","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20000410","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"},{"date":"20010109","type":"SUPPL","sponsor":"NOVO NORDISK INC","applicationNumber":"BLA019991"}],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Novolin 70/30","genericName":"Novolin 70/30","companyName":"Wockhardt","companyId":"wockhardt","modality":"Biologic","firstApprovalDate":"","aiSummary":"Novolin 70/30 is a fixed-ratio insulin combination that replaces or supplements the body's natural insulin to regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}